Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Neuhaus, O; Wiendl, H; Kieseier, BC; Archelos, JJ; Hemmer, B; Stüve, O; Hartung, HP.
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
J Neuroimmunol. 2005; 168(1-2):128-137
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Archelos-Garcia Juan-Jose
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Mitoxantrone is an anti-neoplastic anthracenedione derivative that, based on its immunosuppressive properties, is approved for the treatment of severe forms of relapsing-remitting or secondary progressive multiple sclerosis (MS). Whether the beneficial clinical effects of mitoxantrone in MS are due to a broad immunosuppression, or whether there is a specific mechanism of action remains unknown. Peripheral blood mononuclear cells (PBMCs) from untreated or interferon-beta-treated patients with MS or from healthy donors were stimulated in the presence or absence of mitoxantrone. Irrespective of the source of the cells and the cellular phenotype, mitoxantrone inhibited proliferation of activated PBMCs, B lymphocytes, or antigen-specific T-cell lines (TCLs) stimulated on antigen-presenting cells (APCs) in a dose-dependent manner. For functional analysis, TCLs or APCs were incubated separately with mitoxantrone. Pre-incubation of APC more effectively impaired TCL proliferation than pre-incubation of TCLs. Production of cytokines, expression of activation markers, matrix metalloproteinases, and chemokine receptors were not influenced substantially by mitoxantrone. In contrast, in dendritic cells (DCs), mitoxantrone interfered with the antigen-presenting capabilities. For evaluation of apoptotic cell death of target cells, annexin-V-conjugates and a DNA fragmentation assay were applied. Mitoxantrone induced apoptosis of PBMCs, monocytes and DCs at low concentrations, whereas higher doses caused cell lysis. Our observations suggest that the beneficial effects of mitoxantrone in MS result (i) from its immunosuppressive action based on nonspecific cytotoxic effects on lymphocytes, (ii) by inducing programmed cell death of professional APCs, such as DCs.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Annexin A5 - diagnostic use
Blood Cells - drug effects
Cell Death - drug effects
Cell Differentiation - drug effects
Cells, Cultured - drug effects
Cytokines - genetics
Dendritic Cells - drug effects
Dose-Response Relationship, Drug - drug effects
Drug Interactions - drug effects
Female - drug effects
Flow Cytometry - methods
Gene Expression - drug effects
Humans - drug effects
Immunosuppressive Agents - pharmacology
Male - pharmacology
Matrix Metalloproteinases - metabolism
Mitoxantrone - pharmacology
Multiple Sclerosis - pathology
Neurotoxins - pharmacology
Propidium - diagnostic use
T-Lymphocytes - drug effects
Tetanus Toxin - pharmacology
Thymidine - pharmacology
Tritium - pharmacokinetics

Find related publications in this database (Keywords)
multiple sclerosis
mitoxantrone
immunosuppression
immunomodulation
© Meduni Graz Impressum